U.S. regulators rejected an experimental antibiotic developed by Johnson & Johnson and Basilea Pharmaceutica because its clinical trial data were “unreliable.” The Food and Drug Administration requested two new studies on ceftobiprole, developed with New Brunswick-based Johnson & Johnson and…

Here is the original post:
FDA rejects new Johnson&Johnson antibiotic